Neurocrine Biosciences, Inc. $NBIX Holdings Raised by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 20.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 54,474 shares of the company’s stock after acquiring an additional 9,383 shares during the period. Segall Bryant & Hamill LLC’s holdings in Neurocrine Biosciences were worth $7,647,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Geneos Wealth Management Inc. grew its stake in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $27,000. Quent Capital LLC acquired a new position in Neurocrine Biosciences in the third quarter worth approximately $32,000. Finally, MAI Capital Management raised its position in Neurocrine Biosciences by 101.2% during the second quarter. MAI Capital Management now owns 328 shares of the company’s stock valued at $41,000 after acquiring an additional 165 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on NBIX. TD Cowen boosted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Wells Fargo & Company reduced their price objective on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Truist Financial lowered their target price on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. JPMorgan Chase & Co. cut their target price on Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Finally, Wedbush upped their price target on Neurocrine Biosciences from $149.00 to $151.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.05.

Neurocrine Biosciences Price Performance

NBIX stock opened at $133.44 on Thursday. The stock has a market capitalization of $13.39 billion, a price-to-earnings ratio of 28.64, a price-to-earnings-growth ratio of 0.68 and a beta of 0.32. The company has a 50-day moving average of $135.00 and a two-hundred day moving average of $140.52. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.69 EPS. Equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In related news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Leslie V. Norwalk sold 1,190 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total transaction of $184,557.10. Following the completion of the sale, the director owned 6,239 shares of the company’s stock, valued at approximately $967,606.51. The trade was a 16.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 46,966 shares of company stock valued at $6,474,616. 4.80% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.